NASDAQ · Biotechnology

Silexion Therapeutics Corp (SLXN) Stock

$0.21 -8.64% NASDAQ: SLXN Healthcare

Valuation

MetricValue
Price$0.21
Market Cap$89917
P/E Ratio-0.01
P/B Ratio4.06
P/S Ratio0.00
EPS (TTM)$-8.96
52-Week High$42.00
52-Week Low$0.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-563.11%
ROA-328.73%
ROCE300.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity32.05
Current Ratio2.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-1.0M$-4.0M$-5.0M$-13.0M$12.0M
Net Profit$-1.0M$-3.0M$-5.0M$-16.0M$-12.0M
EPS$-68.63$52.37$-6634.98$-3953.62$-89.60
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$115.0M$9.0M$5.0M$3.0M$7.0M
Total Liabilities$1.0M$16.0M$17.0M$7.0M$5.0M
Cash$0$8.0M$5.0M$1.0M$6.0M
Borrowings$0$0$0$4.0M$0

Latest News

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer GlobeNewswire · Jun 23, 2026 Silexion Therapeutics to Attend BIO International Convention 2026 GlobeNewswire · Jun 16, 2026 Silexion Therapeutics Announces 1-for-10 Reverse Share Split GlobeNewswire · May 26, 2026 Top Premarket Gainers MT Newswires · May 20, 2026 Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-3.0M$-5.0M$-8.0M$-11.0M
Investing Cash Flow$0$-1.0M$1.0M$0$0
Financing Cash Flow$-3.0M$0$0$2.0M$0
Net Cash Flow$0$-2.0M$-4.0M$-3.0M$5.0M
Free Cash Flow$-1.0M$-3.0M$-5.0M$-8.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.05
FCF Yield-11416.29%
Quick Ratio0.94
Interest Coverage1522.83
Return 1Y-97.74%
Return 3Y-99.84%
Return 5Y-99.82%

Ownership

Insiders Held24.16%
Institutions Held1.79%
Institutions Float Held2.36%
Institutional HolderSharesReport Date
Pflug Koory, LLC332026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AZTRAzitra Inc $0.13 -1.59% -0.10 $1.40M 0.00%
ENVBEnveric Biosciences, Inc. $1.45 -4.61% -0.09 $6.49M 0.00%
INDPIndaptus Therapeutics, Inc. $2.51 +5.91% -0.34 $284.24M 0.00%
JSPRJasper Therapeutics, Inc. $0.57 +1.82% -0.36 $9.27M 0.00%
LIPOLipella Pharmaceuticals Inc. $0.07 +0.00% -0.05 $300354 0.00%

About Silexion Therapeutics Corp

Silexion Therapeutics Corp is led by CEO Ilan Hadar, employs 11 people, headquartered in IL, publicly traded since 2024.

Silexion Therapeutics Corp (SLXN) stock trades at $0.21 with a market capitalization of $89917. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of 4.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.21 and $42.00, and currently trades 99.5% below its 52-week high.

On profitability, Silexion Therapeutics Corp generates a return on equity (ROE) of -563.11%, return on capital employed of 300.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides